Table 3. Overlap Propensity Score–Weighted Characteristics and Clinical Outcomes Among ACEI and ARB Usage Groups in Patients Who Tested Positive for SARS-CoV-2.
| Characteristic | All patients who tested positive, %a | |||||
|---|---|---|---|---|---|---|
| ACEI | ARB | ACEI/ARB | ||||
| Yes | No | Yes | No | Yes | No | |
| Count, No. | 116 | 1619 | 98 | 1637 | 212 | 1523 |
| Age, y | 63 | 63 | 64 | 64 | 63 | 63 |
| Male | 57 | 57 | 58 | 58 | 55 | 55 |
| Diabetes | 51 | 51 | 48 | 48 | 46 | 46 |
| CAD | 21 | 21 | 23 | 23 | 22 | 22 |
| Hypertension | 97 | 97 | 92 | 92 | 93 | 93 |
| COPD | 12 | 12 | 16 | 16 | 14 | 14 |
| HF | 15 | 15 | 19 | 19 | 17 | 17 |
| Admitted to hospital | 54 | 39 | 53 | 41 | 53 | 36 |
| OR (95% CI) | 1.84 (1.22-2.79) | 1.61 (1.04-2.50) | 1.93 (1.38-2.71) | |||
| Admitted to ICU | 24 | 15 | 20 | 18 | 22 | 15 |
| OR (95% CI) | 1.77 (1.07-2.92) | 1.16 (0.67-2.02) | 1.64 (1.07-2.51) | |||
| Use of ventilator | 14 | 11 | 14 | 12 | 14 | 11 |
| OR (95% CI) | 1.35 (0.74-2.47) | 1.12 (0.59-2.12) | 1.32 (0.80-2.18) | |||
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; HF, heart failure; ICU, intensive care unit; OR, odds ratio; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
a
Reported is either the overlap propensity score–weighted mean or proportion for each group.